anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Aeglea BioTherapeutics · pitchdeck

Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides

56 pages · 6 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides

Aeglea BioTherapeutics · 2023-07
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

6
coverage by narrative range · generated from this deck JSON
Narrative range 56 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Setup 4 slides 100% 4/4 slides 100% 4/4 slides · 13 hits
— 0/4 slides
25% 1/4 slides
— 0/4 slides
100% 4/4 slides
— 0/4 slides
Problem (Identify pain) 4 slides 100% 4/4 slides 100% 4/4 slides · 24 hits
— 0/4 slides
— 0/4 slides
50% 2/4 slides 100% 4/4 slides 100% 4/4 slides Agitate (Make it worse) 4 slides 100% 4/4 slides 100% 4/4 slides · 22 hits
— 0/4 slides
— 0/4 slides
100% 4/4 slides 100% 4/4 slides 100% 4/4 slides · 8 hits Solution (Provide relief) 18 slides 100% 18/18 slides 100% 18/18 slides · 88 hits
— 0/18 slides
55.6% 10/18 slides 55.6% 10/18 slides 100% 18/18 slides 100% 18/18 slides Evidence 14 slides 100% 14/14 slides 100% 14/14 slides · 69 hits
— 0/14 slides
28.6% 4/14 slides · 6 hits 71.4% 10/14 slides 100% 14/14 slides
— 0/14 slides
Action 12 slides 100% 12/12 slides 100% 12/12 slides · 54 hits
— 0/12 slides
41.7% 5/12 slides · 6 hits 58.3% 7/12 slides 100% 12/12 slides
— 0/12 slides

Slide inventory

56
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Setup
02
other
Open slide detailBeat · Setup
03
The slide details a corporate M&A event and associated private placement financing.summarize
Open slide detailBeat · Setup
04
The slide provides a breakdown of shares and conversion ratios related to a merger and concurrent financing.analyze_data
Open slide detailBeat · Setup
05
The slide uses a pipeline table format to show the progression of various drug candidates (SPY001-SPY230) across discovery, IND-enabling, and clinical stages.plan_implementation
Open slide detailBeat · Problem (Identify pain)Loop · Golden Circle
06
The slide uses a donut chart to compare 2021 and 2028 market sizes, highlighting growth.size_opportunity
Open slide detailBeat · Problem (Identify pain)Loop · Golden Circle
07
size_opportunity
Open slide detailBeat · Problem (Identify pain)Loop · Golden Circle
08
The chart uses a visual metaphor of a 'ceiling' (the 40% remission line) and an arrow to indicate the desired shift in therapeutic performance.frame_problem
Open slide detailBeat · Problem (Identify pain)Loop · Golden Circle
09
present_solution
Open slide detailBeat · Agitate (Make it worse)Loop · Golden Circle
10
The chart compares Cyno Half-Life vs Human Half-Life, showing YTE mAbs outperforming WT mAbs.present_solution
Open slide detailBeat · Agitate (Make it worse)Loop · Golden Circle
11
The slide uses a 'before-after' logic to justify the combination strategy.present_solution
Open slide detailBeat · Agitate (Make it worse)Loop · Golden Circle
12
Uses a Venn diagram to show target overlap and a bar chart to show clinical efficacy improvement.present_solution
Open slide detailBeat · Agitate (Make it worse)Loop · Golden Circle
13
The slide uses a Gantt-style visualization to show the progress of various drug candidates (SPY001-SPY230).plan_implementation
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
14
The slide uses a Gantt-style visualization to show the status of various drug development programs.plan_implementation
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
15
Includes a KOL quote and specific market share metrics for US/EU regions.show_traction
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
16
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.compare_peers
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
17
The slide uses a checkmark/empty circle matrix to highlight competitive differentiation.compare_peers
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
18
The slide uses a central antibody diagram to annotate specific technical improvements over 1st generation mAbs.present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
19
Includes structural biology visualization and dose-response curves for two different adhesion targets.present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
21
The chart compares SPY001 against two vedolizumab datasets (internal and Takeda).show_traction
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
22
Uses YTE modification as a mechanism for half-life extension.compare_peers
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
23
The slide uses a visual timeline/comparison to contrast the competitor's high-frequency, citrate-containing formulation with the company's low-frequency, citratcompare_peers
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
24
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.argue_timing
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
25
Data from GEMINI 1 study; highlights that higher drug concentration does not necessarily correlate with higher efficacy in maintenance.analyze_data
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
26
The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
27
Uses historical peer data (Morphic, Prometheus) to project value inflection points for SPY001.compare_peers
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
28
The slide uses a comparison table to establish competitive positioning.compare_peers
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
29
The slide uses qualitative expert feedback to support quantitative preference share data.illustrate_case
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
30
The slide uses a table-like layout to represent a drug development pipeline.plan_implementation
Open slide detailBeat · Solution (Provide relief)Loop · Quick Win Big Bet
31
The chart uses a horizontal bar format to compare clinical remission percentages across different drug targets (TL1A, a4b7, IL-23s, TNFa, S1P1s, JAKs).compare_peers
Open slide detailBeat · Evidence
32
The slide uses a checkmark matrix to highlight the superiority of SPY002.compare_peers
Open slide detailBeat · Evidence
33
The slide uses a Y-shaped antibody diagram to annotate specific technical improvements.present_solution
Open slide detailBeat · Evidence
34
Includes visual representation of antibody binding mechanisms.compare_peers
Open slide detailBeat · Evidence
35
The slide uses two charts: a dose-response curve (left) and a scatter plot (right) to demonstrate competitive advantage.present_solution
Open slide detailBeat · Evidence
36
present_solution
Open slide detailBeat · Evidence
37
The visual uses a mountain-climbing metaphor to represent indication expansion.present_solution
Open slide detailBeat · Evidence
38
The slide uses a matrix-like layout to map targets and programs against development stages.plan_implementation
Open slide detailBeat · Evidence
39
The slide uses a biological process diagram to illustrate the mechanism of action for three drug candidates.present_solution
Open slide detailBeat · Evidence
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.compare_peers
Open slide detailBeat · Evidence
41
The slide uses donut charts to represent remission rates and highlights the safety advantages of gut-selective backbones.compare_peers
Open slide detailBeat · Evidence
42
The slide uses a timeline-based process diagram to illustrate the clinical trial strategy.plan_implementation
Open slide detailBeat · Evidence
43
The slide uses a Y-shaped antibody illustration to represent the combination therapy approach.present_solution
Open slide detailBeat · Evidence
44
The slide uses a Venn diagram to illustrate target overlap and a tree diagram to show potential combination therapy paths.present_solution
Open slide detailBeat · Evidence
45
The slide uses a comparative framework to validate the efficacy of CDx-guided patient selection.show_traction
Open slide detailBeat · Action
46
transition
Open slide detailBeat · Action
47
The slide uses a grid layout for headshots and a logo cloud at the bottom.other
Open slide detailBeat · Action
48
The slide uses a table-based timeline structure to map specific drug candidates (SPY001-004) to expected regulatory and clinical milestones.plan_implementation
Open slide detailBeat · Action
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.compare_peers
Open slide detailBeat · Action
50
The slide uses a timeline-based comparison to suggest that Spyre's assets are on a similar trajectory to high-value acquired assets.cite_precedent
Open slide detailBeat · Action
51
state_next_steps
Open slide detailBeat · Action
52
The slide serves as a credibility transfer by showcasing the partner's team and achievements.cite_precedent
Open slide detailBeat · Action
53
present_solution
Open slide detailBeat · Action
54
The slide uses a pentagon diagram to represent the five pillars of their antibody engineering platform.present_solution
Open slide detailBeat · Action
55
The diagram illustrates the mechanism of FcRn-mediated antibody recycling, contrasting physiological affinity with high affinity.present_solution
Open slide detailBeat · Action
56
Includes two distinct chart types: a scatter plot for half-life correlation and bar charts for ADA rates.present_solution
Open slide detailBeat · Action